Table 1.
Demographic and clinical data of obese and nonobese patients.
| Study | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Gozen et al. | Brown et al. | Wiltz et al. | Ahlering et al. | |||||||
| Normal: BMI < 25 | Overweight: BMI 25–30 | Obese: BMI > 30 | Nonobese: BMI < 30 | Obese: BMI > 30 | Normal: BMI < 25 | Overweight: BMI 25–30 | Obese: BMI > 30 | Obese: BMI > 30 | Nonobese: BMI < 30 | |
| Patients | 425 | 594 | 205 | 97 | 54 | 216 | 464 | 265 | 19 | 81 |
| Age (years) | 64.1 (40–82) | 63.9 (44–84) | 63.5 (49–75) | 58 ± 6 | 57 ± 6 | 60.3 ± 7.1 | 59.7 ± 6.5 | 59.4 ± 6.2 | 62.6 (53–70) | 62.3 (43–78) |
| Preoperative PSA (ng/mL) | ||||||||||
| Mean | - | - | - | 6.2 ± 4.1 | 6.8 ± 3.8 | 6.3 ± 5.1 | 6.4 ± 3.9 | 6.4 ± 4.3 | 7.4 (0.1–21.9) | 8.1 (1.1–62) |
| <4 ng/ml | 50 (12) | 71 (12) | 27 (13) | - | - | 42 (19) | 92 (20) | 58 (22) | - | - |
| 4–10 ng/ml | 223 (52) | 318 (53) | 108 (53) | - | - | 155 (72) | 313 (67) | 178 (67) | - | - |
| >10 ng/ml | 152 (36) | 205 (34) | 70 (34) | - | - | 19 (9) | 59 (13) | 29 (11) | - | - |
| Preoperative Gleason score | ||||||||||
| <7 | 191 (56) | 260 (56) | 93 (59) | 79 (85) | 41 (79) | 141 (65) | 294 (63) | 168 (63) | 44 (54) | 11 (58) |
| 7 | 122 (36) | 172 (37) | 55 (35) | 12 (13) | 5 (10) | 58 (27) | 138 (30) | 83 (31) | 26 (32) | 5 (26) |
| 8–10 | 29 (8) | 32 (7) | 9 (6) | 2 (2) | 6 (12) | 17 (7) | 32 (7) | 14 (6) | 11 (14) | 3 (16) |
| Clinical stage | ||||||||||
| cT1 | 110 (26) | 119 (20) | 31 (15) | 71 (76) | 43 (84) | |||||
| cT2 | 211 (50) | 296 (50) | 95 (46) | 22 (24) | 8 (16) | |||||
| cT3 | 104 (24) | 179 (30) | 79 (39) | - | - | |||||
| cT1c | 181 (84) | 342 (74) | 186 (70) | - | - | |||||
| cT2a | 25 (12) | 89 (19) | 62 (23) | - | - | |||||
| cT2b/c | 10 (4) | 33 (7) | 17 (7) | - | - | |||||
| Surgical technology | LRP | LRP | RLRP | RLRP | ||||||
| Operation time (min) | 197 (102–465) | 210 (113–450) | 219 (110–484) | 192 ± 34 | 208 ± 43 | 217 ± 58 | 214 ± 65 | 234 ± 77 | 295.8 (186–645) | 236.1 (160–490) |
| EBL (mL) | 727 (100–1010) | 767 (100–1080) | 904 (300–1090) | - | - | 199 ± 152 | 215 ± 203 | 231 ± 172 | 183 (50–400) | 105 (25–350) |
| Nerve sparing | ||||||||||
| No | 242 (57) | 382 (64) | 153 (75) | - | - | 9 (4) | 32 (7) | 26 (10) | 5 (26) | 13 (16) |
| Unilateral | 61 (14) | 86 (15) | 25 (12) | - | - | 52 (24) | 120 (26) | 74 (28) | 5 (26) | 20 (25) |
| Bilateral | 122 (29) | 126 (21) | 27 (13) | - | - | 155 (72) | 312 (67) | 165 (62) | 9 (48) | 48 (59) |
| PSM | 79 (18.6) | 127 (21.4) | 60 (29.3) | 22 (23) | 12 (23) | 37 (17) | 79 (17) | 59 (22) | 3 (16) | 22 (27) |
| Catheterization (days) | 7 (5–28) | 7 (4–27) | 7 (4–17) | - | - | 6.0 ± 1.1 | 6.0 ± 1.3 | 6.0 ± 1.8 | - | - |
| Hospital stay (days) | 10 (5–23) | 11 (4–20) | 11 (4–25) | 2.1 ± 1 | 2.1 ± 1.2 | 1.2 ± 0.6 | 1.2 ± 1.2 | 1.2 ± 1.5 | 41 (18–96) | 28.4 (18–168) |
| Complications | 55 (12.9) | 84 (14.1) | 27 (13.2) | 16 (16) | 4 (7) | 22 (10.4) | 49 (10.9) | 37 (14.5) | 5 (26.3) | 4 (4.9) |
| Postoperative Gleason score | ||||||||||
| <6 | 238 (57) | 305 (53) | 96 (47) | 71 (74) | 36 (69) | 130 (60) | 246 (53) | 140 (53) | 12 (63) | 43 (53) |
| 7 | 143 (34) | 229 (40) | 86 (43) | 25 (26)+ | 16 (31)+ | 71 (33) | 189 (41) | 109 (41) | 6 (32) | 24 (30) |
| 8–10 | 39 (9) | 40 (7) | 20 (10) | - | - | 15 (7) | 29 (6) | 16 (6) | 1 (5) | 14 (17) |
| Pathological stage | ||||||||||
| T0/2 | 273 (64) | 338 (57) | 112 (55) | 81 (84) | 42 (79) | 180 (83) | 373 (80) | 204 (77) | 16 (84) | 59 (73) |
| pT3/4 | 152 (36) | 236 (43) | 93 (45) | 15 (16) | 11 (21) | 36 (17) | 91 (20) | 61 (23) | 3 (16) | 22 (27) |
| Biochemical recurrence | 74 (17.4) | 101 (17) | 33 (16.1) | 3 (5) | 2 (6) | 12 (1.5) | 20 (2.5) | 13 (1.6) | - | - |
BMI = body mass index, PSM = positive surgical margin, EBL = estimated blood loss, LRP = laparoscopic radical prostatectomy, and RLRP = robotic-assisted laparoscopic radical prostatectomy.